Crospon receives CE Mark for EndoFLIP System
31 January 2009
Irish medical device developer Crospon has announced that its
EndoFLIP system has received CE Mark certification from the NSAI
(National Standards Authority of Ireland), the Irish Notified Body, in
accordance with the European Medical Device Directive.
Crospon Limited develops minimally invasive medical devices for
monitoring, diagnosis and therapy for gastroenterology. EndoFLIP is a
diagnostic tool for assessing the competence of the gastroesophageal
junction in patients with gastroesophageal reflux disease (GERD).
John O’Dea, CEO Crospon Ltd, said, “Today’s announcement is an
important step in the company’s development and ensures Crospon remains
on schedule to release the EndoFLIP system into the European market by
the end of the first quarter of 2009.”
In December 2008, Crospon announced that it had completed an
additional €500,000 funding round, following on from the completion of a
€3m round of financing earlier that year. It says that this additional
funding will be primarily used for the completion of development,
manufacturing startup and preparation to market of the EndoFLIP system.
EndoFLIP is used to enhance diagnosis and assist in the surgical
treatment of gastroesophageal reflux disorder (GERD). The EndoFLIP
system is the first is a range of products the company plans to bring to
market.
Bookmark this page